Cowen & Co. Believes Bluebird Bio (NASDAQ: BLUE) Won’t Stop Here

By Jason Carr

Cowen & Co. analyst Eric Schmidt reiterated a Buy rating on Bluebird Bio (NASDAQ: BLUE) today. The company’s shares opened today at $112, close to its 52-week high of $123.75.

According to, Schmidt is a top 100 analyst with an average return of 32.7% and a 63.2% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Bluebird Bio has an analyst consensus of Moderate Buy, with a price target consensus of $99.30.

The company has a one year high of $123.75 and a one year low of $36.62. Currently, Bluebird Bio has an average volume of 826.6K.

Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is neutral on the stock. Most recently, in April 2017, Jason Cole, the SVP, Secy. & General Counsel of BLUE bought 3,750 shares for a total of $84,488.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.,05N2D8-E